Fibrinogen composition, method and wound articles

ABSTRACT

Disclosed is a fibrinogen composition. The fibrinogen composition comprises denatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-% and a fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel. In some examples, the fibrinogen composition is dehydrated denatured fibrinogen hydrogel, where the fibrinogen composition comprises salt at a concentration no greater than 20 wt.-%.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.16/338,803, filed Apr. 2, 2019, which is a national stage filing under35 U.S.C. 371 of PCT/US2017/055015, filed Oct. 4, 2017, which claims thebenefit of U.S. Provisional Application No. 62/404,507, filed Oct. 5,2016, the disclosures of which are incorporated by reference in theirentirety herein.

SUMMARY

In one embodiment, a method of forming a fibrinogen hydrogel compositionis described. The method comprises providing a fibrinogen hydrogel orprecursor thereof, comprising fibrinogen hydrogel forming salt. Thefibrinogen hydrogel forming salt concentration is greater than or equalto the threshold concentration to form a fibrinogen hydrogel. The methodfurther comprises denaturing the fibrinogen hydrogel such as by heating.The method optionally further comprises combining the fibrinogenhydrogel with a carrier material. When present, the concentration of thecarrier material typically ranges from 0.1 to about 50 wt.-%. The methodfurther comprises reducing the salt concentration below the thresholdconcentration to form a fibrinogen hydrogel. The step of reducing thesalt concentration can occur before and/or after combining thefibrinogen hydrogel with the carrier material. The fibrinogen hydrogelprecursor may comprise an aqueous solution comprising fibrinogen and afibrinogen hydrogel forming salt. The salt typically comprises a sodiumcitrate optionally in combination with NaCl. The threshold saltconcentration of the aqueous solution is at least 0.45 wt.-%, or 0.50wt.-%, or 0.6 wt.-%, or 0.7 wt.-%, or 0.8 wt.-% or 0.9 wt.-%. In someembodiments, the aqueous solution further comprises a fibrinogenhydrogel plasticizer.

In another embodiment, a fibrinogen composition is described comprisinga denatured fibrinogen hydrogel having a fibrinogen concentrationranging from 0.1 to 15 wt.-%; optional carrier material, and afibrinogen hydrogel forming salt. When present, the concentration of thecarrier material typically ranges from 0.1 to about 50 wt.-%. Thefibrinogen hydrogel forming salt has a concentration less than athreshold concentration to form the fibrinogen hydrogel. In typicalembodiments, the denatured fibrinogen hydrogel is at least partiallydehydrated.

In another embodiment, a fibrinogen composition is described comprisinga dehydrated denatured fibrinogen hydrogel and salt at a concentrationno greater than 20 wt.-%. The dehydrated denatured fibrinogencomposition may optionally be interdispersed with 0.5 to 99 wt.-% of acarrier material.

The dehydrated denatured fibrinogen hydrogel composition typically has asalt concentration no greater than 20, 15, 10, or 5 wt.-%. Thedehydrated denatured fibrinogen hydrogel or fibrinogen composition canbe in various physical forms such a sheet, foam, or plurality of pieces.

The carrier material is typically not water, fibrinogen hydrogelplasticizer, or mixture thereof. In some embodiments, the carriermaterial is a polymer. The carrier material may optionally furthercomprise a swelling agent and/or a modifying polymer.

In another embodiment, a method of forming a fibrinogen article isdescribed comprising providing a (e.g. dehydrated) denatured fibrinogencomposition as described herein and disposing the composition on orwithin a carrier layer, such as a skin adhesive, release liner, apolymeric film, a polymeric foam, or a nonwoven or woven fibrousmaterial.

In other embodiments, wound dressings are described comprising a (e.g.dehydrated) denatured fibrinogen composition as described herein aloneor in combination with a carrier material.

In another embodiment, a method of treatment of a wound is describedcomprising providing a (e.g. dehydrated) denatured fibrinogencomposition or wound dressing as described herein, and providing thecomposition proximate a wound. The fibrinogen composition can increasethe rate of re-epithelialization and/or wound healing biological markerssuch as VEGF, EGF, MMP1, MMP8, MMP9, and TIMP-1.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic cross-section of an illustrative embodiment of afibrinogen article suitable for a wound dressing comprising a fibrinogencomposition in the form of a sheet;

FIG. 2 is a schematic cross-section of an illustrative embodiment of afibrinogen article suitable for a wound dressing comprising a fibrinogencomposition in the form of a sheet of foam;

FIG. 3 is a schematic cross-section of an illustrative embodimentfibrinogen article suitable for a wound dressing comprising a sheet offoam and fibrinogen particles;

FIG. 4 is a schematic cross-section of an illustrative embodiment of afibrinogen article suitable for a wound dressing comprising afibrinogen-containing layer and a carrier layer;

FIG. 5 is a schematic cross-section of an illustrative embodiment of afibrinogen article suitable for a wound dressing comprising afibrinogen-containing layer, a carrier layer, and a (e.g. pressuresensitive) adhesive;

FIG. 6 is a schematic cross-section of an illustrative embodiment of afibrinogen article suitable for a wound dressing comprising a carrierlayer, a (e.g. pressure sensitive) adhesive; and (e.g. dehydrated)fibrinogen hydrogel containing particles;

FIG. 7 is a schematic cross-section of an illustrative embodiment of afibrinogen article suitable for a wound dressing comprising a carrierlayer, an absorbent, a (e.g. pressure sensitive) adhesive; andfibrinogen-containing layer;

FIG. 8 is a schematic cross-section of an illustrative carrier layer andfibrinogen-containing layer comprising a discontinuous skin adhesive and(e.g. dehydrated) fibrinogen hydrogel containing particles;

FIG. 9 is a schematic cross-section of another illustrative embodimentof a fibrinogen article suitable for a wound dressing comprising acarrier layer, fibrinogen-containing layer, skin contact pressuresensitive adhesive, and release liner;

FIG. 10 is a top plan view of the wound-facing surface of the article ofFIG. 10;

FIG. 11 is a schematic cross-section of another illustrative embodimentof a fibrinogen article suitable for a wound dressing comprising acarrier layer, fibrinogen-containing layer, skin contact pressuresensitive adhesive, and release liner.

DETAILED DESCRIPTION

In one embodiment, a method of forming a fibrinogen hydrogel compositionis described. Fibrinogen is a precursor to fibrin. As used herein,“fibrin” refers to a protein formed by the reaction of fibrinogen with afibrin-forming enzyme (e.g. thrombrin). Such enzyme is capable ofcleaving fibrin A and B peptides from fibrinogen and convert it tofibrin.

The method comprises providing a fibrinogen hydrogel or precursorthereof, comprising fibrinogen hydrogel forming salt.

The precursor thereof typically comprises an aqueous solution comprisingfibrinogen and salt.

The aqueous solution generally comprises a sufficient amount offibrinogen. In some embodiments, the amount of fibrinogen in the aqueoussolution is at least 5, 6, 7, 8, 9, or 10 wt.-% and typically no greaterthan about 15 wt.-%. At concentrations of 15 wt-.% and greater, theviscosity can be come undesirably high.

The viscosity of the aqueous solution of fibrinogen is typically atleast 50 or 100 cps and no greater than about 1000 cps. In someembodiments, the viscosity is less than 900, 800, 700, 600, or 500 cps.

Aqueous solutions of fibrinogen typically comprise salt (e.g. saline).The salt concentration is sufficient such that the fibrinogen forms asolution. Alternatively, solid fibrinogen can be reconstituted in salineor other salt solution.

The aqueous solution further comprises salt suitable for producing afibrinogen containing hydrogel. Thus, such salt can be characterized asa fibrinogen hydrogel forming salt. The fibrinogen is generallyuniformly dispersed and soluble in the hydrogel. Hence, the hydrogeltypically contains little or no fibrinogen precipitates. When afibrinogen hydrogel is formed, the hydrogel is generally a continuoustwo-phase system that can be handled as a single mass.

Various salts with Group I and/or Group II metal cations have beenutilized to solubilize protein such as potassium, sodium, lithium,magnesium, and calcium. Other cations utilized in protein synthesisinclude citrate, ammonium and guanidinium.

Various anions have also been utilized to solubilize protein. Althoughchloride anion is most common, nitrate and acetate are most similar tochloride according to the Hofmeister series, i.e. a classification ofions in order of their ability to salt out (e.g. precipitate) or salt in(e.g. solubilize) proteins.

In some embodiments, the salt comprises sodium chloride. The amount ofsodium chloride in the aqueous solution and fibrinogen hydrogel, priorto dehydration, is typically greater than 0.09 wt.-% of the solution.The concentration of sodium chloride may be at least 0.10, 0.20, 0.30,0.04, 0.50, 0.60, 0.70, 0.80 or “normal saline” 0.90 wt.-% and typicallyno greater than 1 wt.-%. Minimizing the salt concentration is amenableto minimizing the salt that is subsequently removed.

The salt typically comprises a calcium salt, such as calcium chloride.The amount of calcium salt in the aqueous solution and fibrinogenhydrogel, prior to dehydration, is typically at least 0.0015%, 0.0020%,or 0.0030% wt.-% and typically no greater than 0.5 wt.-%.

In some embodiments, the salt comprises sodium citrate (i.e. trisodiumcitrate Na₃C₆H₅O₇). Commercially available fibrinogen can contain sodiumcitrate. The amount of sodium citrate can be at least 1, 2, 3, 4, or 5wt.-% solids ranging up to 10, 11, 12, 13, 14 or 15 wt.-% solids.Commercially available fibrinogen can also contain sodium chloride. Theamount of sodium chloride can be at least 1, 2, 3, 4, or 5 wt.-% solidsranging up to 10, 11, 12, 13, 14, or 15 wt.-% solids.

In some embodiments, a buffering agent may be present to maintain thedesired pH range. In some embodiments, the pH ranges from 6 to 8 or 7 to8 during the formation of the fibrinogen. Various buffering agent areknown. Buffering agents are typically weak acids or weak bases. Onesuitable buffering agent is a zwitterionic compound known as HEPES(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). Other bufferingagents, such as those commonly known as Good buffers can also beutilized. In some embodiments, the buffering agent does notsubstantially contribute to the formation of the fibrinogen hydrogel.For example when the salt contains sodium and calcium chloride, thebuffering agent HEPES does not substantially contribute to the formationof the fibrinogen hydrogel. This means that a fibrinogen hydrogel can beformed with the sodium and calcium salts in the absence of HEPES. Thusthe concentration of HEPES in this example, as well as any other saltthat does not substantially contribute to the formation of thefibrinogen hydrogel, is not included in the threshold concentration toform a fibrinogen hydrogel. However, HEPES as well as any other saltthat does not substantially contribute to the formation of thefibrinogen hydrogel can contribute to the total salt concentration ofthe dehydrated fibrinogen hydrogel or fibrinogen composition in theevent such salts are present after reducing the salt concentration, suchas by rinsing.

In some embodiments, the threshold concentration to form a fibrinogenhydrogel is greater than 0.423 wt.-%. The threshold concentration ofsalt to form a gel may be least 0.430 wt.-% or 0.440 wt.-%, and in someembodiments at least 0.450, 0.500, 0.550, 0.600, 0.650, 0.700, 0.750,0.800, 0.850, or 0.900 wt.-% of the aqueous solution. It is appreciatedthat the threshold concentration may vary to some extent depending onthe selection of salt(s). In one embodiment, the salt concentration(e.g. NaCl+Na₃C₆H₅O₇) is 1.1 wt.-%. However, such salt concentration maybe greater than the threshold concentration. The concentration of saltin the (i.e. initially formed) hydrogel is the same as the concentrationof salt in the aqueous solution.

When a fibrinogen hydrogel is formed using a threshold concentration ofsalt and the hydrogel is dehydrated, the resulting dehydrated fibrinogenhydrogel has an even greater concentration of salt. For example, thefibrinogen hydrogel forming salt (e.g. Na₃C₆H₅O₇, NaCl, CaCl₂)concentration is greater than 10, 15, 20, 25, or 30 wt.-%. As describedin US2016/024141, high salt concentrations can cause (e.g. dermal)tissue irritation and damage during the healing process as indicated byinflammatory cell infiltration as well as collagen degeneration andmineralization.

The present method of preparing a fibrinogen composition comprisesforming a fibrinogen hydrogel from an aqueous composition as previouslydescribed, denaturing the fibrinogen hydrogel, and reducing the saltconcentration below the threshold salt concentration to form a denaturedfibrinogen hydrogel. For embodiments wherein the (e.g. dehydrated)denatured fibrinogen hydrogel is utilized for wound healing, the methodcomprises reducing the salt concentration below the concentration thatcan cause (e.g. dermal) tissue irritation and damage during the healingprocess.

The most common way of denaturing the fibrinogen hydrogel is by heating.For example, the fibrinogen hydrogel may be heated to a sufficienttemperature (e.g. 80° C.) for a sufficient period of time. The denaturedfibrinogen hydrogen can exhibit a clear appearance.

In typical embodiments, the step of reducing the salt concentrationcomprises rinsing the denatured fibrinogen hydrogel alone or incombination with a carrier material with a solution capable ofdissolving the salt. The solution is typically aqueous comprising atleast 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 wt.-%, or greater byvolume water. The rinsing solution may further contain other watermiscible liquids such as plasticizers. The denatured fibrinogen hydrogelis typically rinsed with a volume of solution at least 1, 2, 3, 4, 5, 6,7, 8, 9, or 10 times greater than the volume of the hydrogel. To reducethe salt concentration even further, the denatured fibrinogen hydrogelmay be rinsed with a volume of solution 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 times greater than the volume of the hydrogel. Another way ofreducing the salt includes reacting the cation and/or anion of the salt,or in other words complexing the salt, such that the salt no longerforms ions in an aqueous solution such as bodily fluids of wounds.Another way of reducing the salt concentration is diluting withfibrinogen hydrogel plasticizer and/or by the addition of a carriermaterial. Further, various combination of these methods can be used.

The amount of fibrinogen hydrogel forming salt (e.g. NaCl+CaCl₂))removed from the fibrinogen hydrogel alone or in combination with acarrier material can depend on the amount of salt in the aqueous (e.g.starting) solution and thus, the amount of salt in the initially formedhydrogel. For example, when the aqueous (e.g. starting) solutioncomprises about 0.9 wt.-% salt, at least about 35 wt.-% of the salt isremoved from the fibrinogen hydrogel. However, when the aqueous (e.g.starting) solution comprises about 1.25 wt.-% salt, greater than 50% ofthe salt is removed from the fibrinogen hydrogel. In some embodiments,at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% of thesalt is removed from the hydrogel. In other embodiments, at least 91,92, 93, 94, 95, 96, 97, 98, or 99% of the salt is removed from thehydrogel. If the threshold concentration is less than 0.9 wt.-%, theamount of salt removed can be less than 35 wt.-%. In such embodiment, atleast 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45% of the salt isremoved from the hydrogel.

The denatured fibrinogen hydrogel alone or in combination with a carriermaterial having the reduced fibrinogen hydrogel forming salt content isthen dehydrated using any number of methods. This step may be referredto as dehydrating, drying or desiccating the hydrogel, all of whichrefer herein to the process of removing water content from the hydrogelas possible. Dehydration can therefore be accomplished using heat,vacuum, lyophilization, desiccation, filtration, air-drying, and thelike. In some embodiments, the dehydrating is accomplished byfreeze-drying, oven drying, a low pressure nitrogen steam, or acombination thereof. In some embodiments, lyophilization may bepreferred since the resulting fibrinogen material is less likely toswell once in contact with an aqueous solution. However, the oven-driedfibrinogen gel sheets were observed to be more transparent and moreuniform than the lyophilized sheets. The dehydration step may occur overa range of time, depending on the particular method used and the volumeof the hydrogel. For example, the step may last for a few minutes, a fewhours, or a few days. The present disclosure is not intended to belimited in this regard.

The dehydrated denatured fibrinogen hydrogel, optionally furthercomprising a carrier material, generally has a (e.g. hydrogel forming)salt concentration less than 30 wt.-% or 25 wt.-% (e.g. for a watercontent of zero ranging up to no greater than 20 wt.-%). When thedehydrated denatured fibrinogen hydrogel as well as the fibrinogencomposition is intended for use for wound healing the salt concentrationis less than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5,4, 3, 2, or 1 wt.-% (e.g. for a water content of zero ranging up to nogreater than 20 wt.-%). In some embodiments, the dehydrated denaturedhydrogel as well as the fibrinogen composition has a water content nogreater than 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4,3, 2, or 1 wt.-% or less. In some embodiments, the total saltconcentration including the buffering salts are also within theconcentration ranges just described. In some embodiments, the dehydrateddenatured hydrogel will swell when combined with water (i.e.rehydrated).

The salt concentration of the dehydrated fibrinogen hydrogel, optionallyfurther comprising a carrier material, can be calculated when the kindsand amounts of salt utilized to prepare the fibrinogen hydrogel areknown and the salt has not been removed, such as by rinsing with anaqueous solution. The salt concentration of the (e.g. dehydrated)denatured fibrinogen hydrogel composition, optionally further comprisinga carrier material, having a reduced salt concentration, can bedetermine by measuring the conductivity of an aqueous solutioncontaining a specified amount (1% w/w) using a suitable instrument suchas a VWR Symphony B30PCI Benctop Multi Parameter Meter-pH, Conductivity,ISE.

Quantitative and qualitative analysis of salt can be conducted using ionchromatography, as well as other techniques.

The fibrinogen hydrogel alone or in combination with a carrier materialis dehydrated to reduce the water content and thereby increase thefibrinogen concentration. Higher fibrinogen concentrations generallypromote healing more rapidly than lower fibrinogen concentrations. Thefibrinogen hydrogel, prior to dehydration typically comprises about 0.5wt.-% to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 wt.-% fibrinogen. Afterdehydration, the fibrinogen composition typically comprises at least 10,15, 20, 25, 30, 35, 40, 45, or 50 wt.-% fibrinogen. The fibrinogenconcentration of the dehydrated fibrinogen hydrogel composition istypically no greater than 99 wt.-% and in some embodiments no greaterthan 95, 90, 85, or 80 wt-%.

The dehydrated denatured fibrinogen hydrogel, optionally furthercomprising a carrier material, typically has a water content of at least1, 2, 3, 4, or 5 wt.-%. In some embodiments, the dehydrated fibrinogenhydrogel has a water content of at least about 10, 15, or 20 wt.-%. Inother embodiments, the water content is no greater than 10 wt.-%.

The (e.g. dehydrated) fibrinogen hydrogel, optionally further comprisingcarrier material, may include an amount of fibrinogen in a range from0.1 wt.-% to 10 or 15 wt.-% relative to a total weight. In someembodiments, the (e.g. dehydrated) denatured fibrinogen hydrogel,optionally further comprising carrier material, includes fibrinogen inan amount no greater than 5, 4, 3, 2, 1, 0.1 or 0.05 wt.-%, relative toa total weight of the (e.g. dehydrated) fibrinogen hydrogel.

In some embodiments, the (e.g. dehydrated) fibrinogen hydrogel,optionally further comprising a carrier material, further comprises aplasticizer. Various water-miscible plasticizers are suitable forhydrogels. Such plasticizers typically comprise hydroxyl groups.Suitable plasticizers include for example C₃-C₂₄ sugar alcohols such asglycerol, diglycerol, triglycerol, xylitol, and mannitol as well asC₃-C₂₄ alkane diols such as butane diol and propane diol. In someembodiments, the plasticizer comprises an alkylene group having nogreater than 12 carbons atoms. The (e.g. dehydrated) fibrinogen hydrogelmay contain a single plasticizer or combination of plasticizers. Whenplasticizer is present, the concentration typically ranges from 0.5wt.-% to 2 wt.-% of the aqueous starting precursor solution. Thedehydrated hydrogel as well as the fibrinogen composition may compriseat least 5, 10, 15 or 20 wt.-% and typically no greater than 80, 70, 60,50, or 40 wt-% plasticizer.

Inclusion of a plasticizer can result in a flexible dehydratedfibrinogen hydrogel composition, the properties of which can bedetermined by standard tensile and elongation testing. The film offlexible dehydrated fibrinogen hydrogel for testing can have a thicknessof at least 10, 15 or 20 microns and typically no greater than 2 mm, 1mm, 500 microns, or 250 microns. In some embodiments, the thickness isno greater than 200, 150, 100, 75, or 60 microns. The elongation canrange from 10, 15, or 20% to 1000%. In some embodiments, the elongation(e.g. of a 50 micron film) is at least 50% or 75% and no greater than200%, 150%, or 100%. The ultimate tensile strength is typically at least0.1, 0.2, or 0.3 MPa and is typically no greater than 150 MPa. In someembodiments, the ultimate tensile strength (e.g. of a 50 micron film) isno greater than 50, 25, 10, or 5 MPa. The Young's elastic modulus istypically at least 0.5, 0.6, 0.7, 0.8, 0.9 or 1 MPa and is typically nogreater than about 2000 MPa. In some embodiments, the Young's elasticmodulus (e.g. of a 50 micron film) is at least 2 or 3 MPa and typicallyno greater than 100, 75 or 50 Mpa. Inclusion of the carrier material,especially those containing polymer(s), can also provide fibrinogenfilms having the tensile and elongation properties just described.

The (e.g. dehydrated) denatured fibrinogen hydrogel, optionally furthercomprising a carrier material, can include various additives, providedthe additives do not detract from forming the fibrinogen hydrogel andreducing the salt concentration therefrom. Examples of additives caninclude any of antimicrobial agents, anti-inflammatory agents, topicalanesthetics (e.g., lidocaine), other drugs, growth factors,polysaccharides, glycosaminoglycans. If an additive is included, itshould be included at a level that does not interfere with the activityof the fibrinogen containing layer with respect to promoting healing ofthe wound.

Antimicrobial agents are agents that inhibit the growth of or killmicrobes such as bacteria, mycobacteria, viruses, fungi, and parasites.Anti-microbial agents therefore include anti-bacterial agents,anti-mycobacterial agents, anti-viral agents, anti-fungal agents, andanti-parasite agents. Fibrinogen containing layers so loaded can be usedto prevent or control infection.

Anti-inflammatory agents are agents that reduce or eliminateinflammation. Examples include alclofenac, alclometasone dipropionate,algestone acetonide, alpha amylase, amcinafal, amcinafide, amfenacsodium, amiprilose hydrochloride, anakinra, anirolac, anitrazafen,apazone, balsalazide disodium, bendazac, benoxaprofen, benzydaminehydrochloride, bromelains, broperamole, budesonide, carprofen,cicloprofen, cintazone, cliprofen, clobetasol propionate, clobetasonebutyrate, clopirac, cloticasone propionate, cormethasone acetate,cortodoxone, deflazacort, desonide, desoximetasone, dexamethasonedipropionate, diclofenac potassium, diclofenac sodium, diflorasonediacetate, diflumidone sodium, diflunisal, difluprednate, diftalone,dimethyl sulfoxide, drocinonide, endrysone, enlimomab, enolicam sodium,epirizole, etodolac, etofenamate, felbinac, fenamole, fenbufen,fenclofenac, fenclorac, fendosal, fenpipalone, fentiazac, flazalone,fluazacort, flufenamic acid, flumizole, flunisolide acetate, flunixin,flunixin meglumine, fluocortin butyl, fluorometholone acetate,fluquazone, flurbiprofen, fluretofen, fluticasone propionate,furaprofen, furobufen, halcinonide, halobetasol propionate, halopredoneacetate, ibufenac, ibuprofen, ibuprofen aluminum, ibuprofen piconol,ilonidap, indomethacin, indomethacin sodium, indoprofen, indoxole,intrazole, isoflupredone acetate, isoxepac, isoxicam, ketoprofen,lofemizole hydrochloride, lornoxicam, loteprednol etabonate,meclofenamate sodium, meclofenamic acid, meclorisone dibutyrate,mefenamic acid, mesalamine, meseclazone, methylprednisolone suleptanate,morniflumate, nabumetone, naproxen, naproxen sodium, naproxol, nimazone,olsalazine sodium, orgotein, orpanoxin, oxaprozin, oxyphenbutazone,paranyline hydrochloride, pentosan polysulfate sodium, phenbutazonesodium glycerate, pirfenidone, piroxicam, piroxicam cinnamate, piroxicamolamine, pirprofen, prednazate, prifelone, prodolic acid, proquazone,proxazole, proxazole citrate, rimexolone, romazarit, salcolex,salnacedin, salsalate, sanguinarium chloride, seclazone, sermetacin,sudoxicam, sulindac, suprofen, talmetacin, talniflumate, talosalate,tebufelone, tenidap, tenidap sodium, tenoxicam, tesicam, tesimide,tetrydamine, tiopinac, tixocortol pivalate, tolmetin, tolmetin sodium,triclonide, triflumidate, zidometacin, and zomepirac sodium.

The (e.g. dehydrated) denatured fibrinogen hydrogel, optionally furthercomprising a carrier material, can have various physical forms. In someembodiments, the fibrinogen hydrogel as well as the fibrinogencomposition is formed prior to reducing the salt content. The fibrinogenhydrogel as well as the fibrinogen composition is typically sufficientlyflowable at a temperature ranging from 0° C. to 37° C. such that thefibrinogen hydrogel takes the physical form of the container surroundingthe fibrinogen hydrogel. For, example if the fibrinogen hydrogel as wellas the fibrinogen composition is cast into a rectangular pan, thefibrinogen hydrogel as well as the fibrinogen composition forms into asheet. Thus, the fibrinogen hydrogel as well as the fibrinogencomposition can be cast into various shaped containers or in other wordsmolded to provide (e.g. dehydrated) hydrogel of various shapes andsizes.

In one embodiment, the (e.g. dehydrated) denatured fibrinogen hydrogelas well as the fibrinogen composition further comprising the carriermaterial may be provided as a fibrinogen foam. This can be accomplishedby aerating the fibrinogen solution early in the denaturing process.After formation of the fibrinogen foam, salts can then be removed aspreviously described.

In another embodiment, the (e.g. dehydrated) denatuted fibrinogenhydrogel may be provided as particles. For example, (e.g. dehydrated)fibrinogen hydrogel microbeads may be formed, such as by the methoddescribed in U.S. Pat. No. 6,552,172 (Marx et al.). In yet anotherexample, (e.g. dehydrated) fibrinogen hydrogel particles may be utilizedas microcarriers such as described in US 2010/0291219 (Karp et al.). Thesalt content of the microbeads and microcarriers is reduced below thethreshold concentration to form a fibrinogen hydrogel as previouslydescribed. The microbeads and microcarriers can further comprise carriermaterial as described herein.

In other embodiments, the (e.g. dehydrated) denatured fibrinogenhydrogel, optionally further comprising a carrier material, can beformed after reducing the salt content. For example, a sheet of (e.g.dehydrated) denatured fibrinogen hydrogel optionally further comprisinga carrier material, can be (e.g. laser or die) cut into pieces havingvarious shapes and sizes. In another example, the composition may beground, pulverized, milled, crushed, granulated, pounded, and the like,to produce fibrinogen powder. In some embodiments, methods used formaking (e.g. dehydrated) denatured fibrinogen hydrogel particles aretypically not dependent on oil-in-water emulsions.

When (e.g. dehydrated) denatured fibrinogen hydrogel composition,optionally further comprising a carrier material, are formed intoparticles, the method may further involve size separating the particles.This may be accomplished most easily by sieving the particle compositionthrough one or more appropriate sieves or filters having desired poresizes. In some embodiments the particles can be sieved to arrive atpopulations having average diameters in the range of about 85-180,90-170, 100-160, 100-150, 110-150, 120-140, or about 130 micrometers inaverage diameter. The fibrinogen particles further comprising a carriermaterial may be equal to or less than 80, 90, 100, 110, 120, 130, 140,150, 160, 170, or 180 micrometers, provided they have a minimum averagediameter of at least 10, 20, 30, 40 or 50 micrometers. It is to beunderstood that these average diameters refer to the diameter of thedehydrated particles rather than their rehydrated diameters. Theparticle volume may increase 10-250% of the initial volume afterrehydration.

In some embodiments, the (e.g. dehydrated) denatured fibrinogen hydrogelcontaining particles can be size restricted. In some aspects, thecomposition comprises a plurality of fibrinogen or fibrinogencomposition particles, wherein at least 50% of which have an averagediameter of 85-180 micrometers prior to hydration. In some embodiments,at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, or more of thefibrinogen or fibrinogen composition particles have an average diameterof 85-180 micrometers.

The (e.g. dehydrated) denatured fibrinogen hydrogel containing particlesmay have spherical shape or an irregular non-spherical shape and size.The diameter of a non-spherical particle can be determined by summingits longest and its shortest dimension and dividing that sum by two.This is referred to as the average diameter of a single particle.Average diameter of a population of particles may be deduced based on asieving analysis (i.e., the sieving analysis would provide a range ofaverage diameters based on retention and/or flow through of particles).It will be understood that the term “average diameter” of a populationof particles, defined as “summing its longest and its shortest dimensionand dividing that sum by two”, is conceptually similar to the term“average particle size”, which refers to the “largest dimension” of theparticles in a population of the particles.

In some embodiments, (e.g. dehydrated) denatured fibrinogen hydrogelcontaining particles are provided that are defined by their surfacetopology, topography, or roughness. The surface topology or roughnessmay be expressed in terms of the number and/or size of features (orprotrusions) on the surface of the particles. Roughness can be observedusing techniques commonly used in the art including optical profilometryand atomic force microscopy. The number of features on these particlesmay range from 2-100 typically. The size of these features (orprotrusions) may be expressed in terms of absolute length or in terms ofthe ratio of the size of the feature (or protrusion) and the averagediameter of the particles. In some embodiments, the size of the featureis about 1 micrometer, about 2 micrometers, about 3 micrometers, about 4micrometers, about 5 micrometers, about 6 micrometers, about 7micrometers, about 8 micrometers, about 9 micrometers, about 10micrometers, or more. In other embodiments, the size of the feature ismore than 10 micrometers, more than 15 micrometers, more than 20micrometers, more than 25 micrometers, more than 30 micrometers, morethan 35 micrometers, more than 40 micrometers, more than 45 micrometers,more than 50 micrometers, or more. In still other embodiments, the sizeis 10-100 micrometers. In other embodiments, the size is 1-10micrometers. The ratio of feature size and particle average diameter maybe about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%, or more.This surface roughness is important since it has been found that cellssuch as connective tissue progenitor cells are better able to bind toparticles having a greater degree of surface roughness.

In some embodiments, the (e.g. dehydrated) denatured fibrinogen hydrogelcontaining particles have an average particle size in a range of 0.1microns up to 100 microns. The fibrinogen particles can have an averageparticle size, of at least 0.1, 1, 2, 5, or 10 microns. The averageparticle is typically no greater than 1000 micrometers, 500, 200 or 100microns.

The (e.g. dehydrated) denatured fibrinogen composition described hereinmay be utilized in the treatment of a wound.

To facilitate delivery, the (e.g. dehydrated) denatured fibrinogencomposition (e.g. particles) may be incorporated into a suitable carriermaterial to form various fibrinogen-containing gels, pastes, lotions,creams, and ointments. In another embodiment, (e.g. dehydrated)denatured fibrinogen hydrogel particles can be dispersed in a (e.g.aqueous) liquid carrier material (e.g. an emulsion) to form afibrinogen-containing spray.

The carrier material may be a solid, a liquid, or a mixture of solidsand liquids. In some embodiments, the carrier material is not solelywater, fibrinogen hydrogel plasticizer, or a combination thereof.However, the carrier material may further comprise water and/orfibrinogen hydrogel plasticizer in combination with another carriermaterial, such as a polymer.

In typical embodiments, the carrier material may be characterized asphysiologically inert, nonionic, and pH stable.

In some embodiments, the carrier material is water soluble. The carriermaterial may function as a thickener.

The carrier material, particularly in the case of water solublepolymers, such as polyvinyl N-vinyl lactam polymer, can be characterizedby their Fikentscher K-value as described in Molyneaux, Water-SolublePolymers: Properties and Behavior, Vol. 1, CRC Press, 1983, pp. 151-152.In some embodiments, the carrier material can have a Fikentscher K-valueof at least K-10, K-15, K20, K-25, K-30, or K35. The Fikentscher K-valueof commercially available water soluble polymers typically does notexceed K-120. In some embodiment, the Fikentscher K-value of the carriermaterial is at least K-40, K-50, K60, K70, K80, or K90.

The carrier material, particularly in the case of polymers, may also becharacterized by molecular weight (Mw). In some embodiments, the carriermaterial has a molecular weight of at least 2,500; 5,000; 10,000;25,000; or 50,000 g/mole. The molecular weight of the carrier materialcan range up to 1.5 or 2 million g/mole. In some embodiments, themolecular weight of the carrier material is at least 100,000; 250,000;or 500,000 g/mole.

The K value and molecular weight of the (e.g. polymeric) carriermaterial can even be higher than the ranges described. For example, the(e.g. polymeric) carrier material can be highly crosslinked such that itis no longer soluble in water at 25° C.

The carrier material, particularly in the case of polymers, may also becharacterized by glass transition temperature. In some embodiments, thecarrier material has a Tg of at least 120, 125, or 130° C. The Tg of the(e.g. polymeric) carrier material may range up to about 200° C. In someembodiments, the Tg of the carrier material is at least 140, 150, 160,170, 180 or 190° C. However, the inclusion of swelling agents (e.g.carrier material plasticizer) can reduce the Tg of the carrier material.In this embodiment, the carrier material may have a Tg less than 25° C.or even less than 0° C.

In some embodiments, the carrier material is a film-forming polymer thatforms a polymeric matrix. The (e.g. dehydrated) fibrinogen hydrogel maybe interdispersed with the carrier material as discrete pieces orparticles within the polymeric matrix of the carrier material.Alternatively, the carrier material may be interdispersed with the (e.g.dehydrated) fibrinogen hydrogel as discrete pieces or particles within apolymeric matrix of the (e.g. dehydrated) fibrinogen hydrogel. In otherembodiments, the carrier material (e.g. polymer) and the (e.g.dehydrated) fibrinogen hydrogel are interdispersed within a commonplasticizer.

In some embodiments, (e.g. dehydrated) denatured fibrinogen particlescan be admixed with natural or chemically modified and syntheticbiological carrier materials such as collagen, keratin, gelatin,carbohydrates, and cellulose derivatives. Synthetic biological carriermaterials can also be utilized such as described in previously cited US2010/0291219 (Karp et al.).

In some embodiments, the biological carrier material comprises abioerodible hydrogel such as polyhyaluronic acids, casein, gelatin,glutin, polyanhydrides, polyacrylic acid, alginate, chitosan,poly(methyl methacrylates), poly(ethyl methacrylates),poly(butylmethacrylate), poly(isobutyl methacrylate),poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(laurylmethacrylate), poly(phenyl methacrylate), poly(methyl acrylate),poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecylacrylate).

In other embodiments, the biological carrier material is a biodegradablesynthetic polymer such as polyamides, polycarbonates, polyalkylenes,polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates,polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, poly-vinylhalides, polyvinylpyrrolidone, polyglycolides, polysiloxanes,polyurethanes and co-polymers thereof, alkyl cellulose, hydroxyalkylcelluloses, cellulose ethers, cellulose esters, nitro celluloses,polymers of acrylic and methacrylic esters, methyl cellulose, ethylcellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose,hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate,cellulose acetate butyrate, cellulose acetate phthalate, carboxylethylcellulose, cellulose triacetate, cellulose sulphate sodium salt,poly(methyl methacrylate), poly(ethyl methacrylate),poly(butylmethacrylate), poly(isobutyl methacrylate),poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(laurylmethacrylate), poly(phenyl methacrylate), poly(methyl acrylate),poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecylacrylate), polyethylene, polypropylene, poly(ethylene glycol),poly(ethylene oxide), poly(ethylene terephthalate), poly(vinylalcohols), polyvinyl acetate, poly vinyl chloride, polystyrene, polymersof lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters,polyurethanes, poly(butic acid), poly(valeric acid), andpoly(lactide-cocaprolactone) and polyvinylpyrrolidone.

In some embodiments, the biological carrier material comprises anuncrosslinked or crosslinked N-vinyl lactam polymer. Such polymercomprises polymerized units of N-vinyl lactam monomers. Nonlimitingexamples of N-vinyl lactam monomers include for exampleN-vinyl-2-pyrrolidone; N-vinyl-2-valerolactam; N-vinyl-2-caprolactam;and mixtures of any of the foregoing. In some embodiments, the N-vinyllactam monomer is N-vinyl-2-pyrrolidone. In some embodiments, thepoly(N-vinyl lactam) polymer is a homopolymer of N-vinyl-2-pyrrolidone.

In other embodiments, the biological carrier material is a copolymer ofN-vinyl lactam. Such copolymers further comprise polymerized units of atleast one comonomer. Nonlimiting examples of comonomers include forexample N,N-dimethylacrylamide, acrylic acid, methacrylic acid,hydroxyethylmethacrylate, acrylamide, 2-acrylamido-2-methyl-1-propanesulfonic acid or its salt, and vinyl acetate. A single comonomer orcombination of comonomers can be employed.

In typical embodiments, the N-vinyl lactam copolymer comprises at least50, 60, 70, 80, or 90 weight percent of polymerized units of N-vinyllactam (e.g. N-vinyl-2-pyrrolidone) monomer(s). The N-vinyl lactamcopolymer further comprises at least 10, 20, 30, 40, or 50 weightpercent of polymerized units of comonomer(s).

Noncrosslinked N-vinyl lactam homopolymer and N-vinyl pyrrolidone/vinylacetate copolymers are commercially available. Nonlimiting sources ofcommercially available poly(N-vinyl pyrrolidone) include AldrichChemical Co. of Milwaukee, Wis., BASF of Parsippany, N.J., ISP (GAF) ofWayne, N.J., Dan River Corporation of Danville, Va., Spectrum ChemicalManufacturing Corporation of Gardena, Calif, as well as Ashland Inc,Covington, Ky. as “Plasdone™ povidone”.

In some embodiments, the (e.g. biological) carrier material comprises acrosslinked polymer. The crosslinked polymer may be any of thepreviously described natural or synthetic polymers wherein such polymerhas been crosslinked. Crosslinking increase the molecular weight andK-value as previously described.

In some embodiments, the crosslinked polymer is a crosslinked syntheticpolymer, such as crosslinked poly(N-vinyl lactam). In some embodiments,the (e.g. poly(N-vinyl lactam)) polymer is radiation-crosslinked (i.e.crosslinked by exposure to actinic radiation). The (e.g. poly(N-vinyllactam)) polymer is typically crosslinked while the polymer in a solidform. In other embodiments, the (e.g. poly (N-vinyl lactam)) syntheticpolymer is crosslinked by free-radical polymerization, either in bulk orin solution, of a precursor containing (e.g. N-vinyl lactam) monomer,optionally other monomers, and a crosslinking compound. (See forexample, U.S. Pat. No. 4,931,282; incorporated herein by reference.)

The polymer of the solid carrier material can be provided in any form,Nonlimiting examples of solid forms include particles, pellets, sheets,flakes, and bulk objects of various shapes, and coated objects ofvarious shapes. For example U.S. Pat. Nos. 4,931,282; 5,225,473; and5,389,376, incorporated herein by reference describe solid forms ofpoly(N-vinyl lactam. Typically, the crosslinked (e.g. poly(N-vinyllactam)) polymer is in the form of particles having an average particlesize (as can be determined by microscopy) of less than about 1, 0.5,0.25 cm. In some embodiments, the average particle size is less than1000, 750, or 500 microns. The average particle is typically at about0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 microns. In some embodiments,the average particle size is at least 25, 50, 75 or 100 microns. In someembodiments, the average particle size can be reduced during mixing.Alternatively, the polymer of the carrier material can be provided in aliquid form such as (e.g. an aqueous or organic-solvent based) solution,emulsion, or dispersion.

The carrier material can further comprise a swelling agent that canswell the (e.g. gurar) natural or (e.g. poly(N-vinyl lactam) syntheticpolymer of the carrier material. In some embodiments, the swelling agentalso functions to plasticize the fibrinogen hydrogel. In yet otherembodiments, the swelling agent can swell a modifying polymer, alsopresent in the biological carrier material. The swelling agent isbiocompatible with human skin.

The polymer of the carrier material can have a Swelling Capacity inwater of at least about 15, typically at least about 30, and often atleast about 40 as described in U.S. Pat. No. 5,409,966; incorporatedherein by reference.

Nonlimiting examples of swelling agents include monohydric alcohols(e.g., ethanol, isopropanol, n-propanol), polyhydric alcohols, (e.g.,ethylene glycol, propylene glycol, di propylene glycol, polyethyleneglycol (Molecular Weight between 200 and 600) and glycerin), etheralcohols (e.g., glycol ethers), glycerol, polyglycerols (e.g.diglycerin, triglycerol, polyglycerin-3, hexaglycerol and decaglycerol),sorbitol and polyhydric alcohol ethoxylates (e.g. sorbeth-6, sorbeth-30,glycereth-1 to glycereth-31) methoxides of polyethylene glycol (MethoxyPEG-2 to Methoxy PEG 100), methoxides of polyhydric alcohol ethoxylates(e.g. glycereth-7 methoxide), as well as any other (e.g. polyol)swelling agents that do not cause skin irritation or toxic reaction, andwater. In some embodiments, the previously described fibrinogen hydrogelplasticizers are utilized as a swelling agent. Various mixtures ofswelling agent can also be employed.

Non-volatile and/or volatile swelling agents may be used. Non-volatilityfor the swelling agent is desired not only at room or body temperaturesbut also at the elevated temperatures of processing which range fromabout 75° C. to about 250° C. When the swelling agent in non-volatile,less than ten percent (10%) of a given 50 ml volume, in a 4 oz. jarhaving a 4 cm diameter circular opening, evaporates after exposure to atemperature of 75° C. for one hour.

The swelling agent may comprise a volatile swelling agent in combinationwith a non-volatile swelling agent, such as a mixture of glycerin orpolyethylene glycol with water. In some embodiments, the carriermaterial may comprise solely non-volatile swelling agents such as, forexample, glycerin or polyethylene glycol. In some embodiments, thecarrier material may comprise solely volatile swelling agents such aswater. When the carrier material comprises a swellable polymer incombination with bound water, the carrier material may be characterizedas a second hydrogel.

The swelling agent is typically a liquid. In some embodiments,humectant—type solid swelling agents like sorbitol could be used inconjunction with a co-swelling agent in order to dissolve the humectantsuch that it remains in the liquid swelling agent. Other humectants thatcould also be employed as swelling agents or co-swelling agents include:1,2,6-hexanetriol, acetamide mea, aluminum hydroxide, arginine pca,butoxypropanol, butylene glycol, dimethyl imidazolidinone,dimethylsilanol hyaluronate, dipotassium glycyrrhizate, erythritol,ethoxydiglycol, fructose, glutamine, gluconic acid, glucose, glucoseglutamate, glucuronic acid, glutamic acid, glycogen, glycyrrhizic acid,heilmoor clay, hexacosyl glycol, histidine, hyaluronic acid,hydrogenated honey, hydrogenated starch, hydrolysate, hydrolyzedcollagen, hydrolyzed elastin, hydrolyzed glycosaminoglycans, hydrolyzedkeratin, hydrolyzed silk, hydrolyzed soy protein, hydrolyzed wheatprotein, hydroxyethyl sorbitol, inositol, inositol hexa-pca, lactamidemea, lactic acid, lactitol, lactose, lysine pca, magnesium pca,maltitol, manganese pca, mannitol, mel (honey extract), menthyl pca,methyl gluceth-10, methyl gluceth-20, pca (pidolic acid), lactamide,polydextrose, polyglucuronic acid, polyglyceryl sorbitol, potassium pca,ppg-20 methyl glucose ether, ppg-38-buteth-37, saccharide isomerate,serica, silk amino acids, sodium carboxymethyl chitin, sodium lactate,sodium mannuronate methylsilanol, sodium pca, sodium pca methylsilanol,sodium polyglutamate, soluble collagen, sorbitol, sucrose, tea-lactate,tea-pca, trehalose, trilactin, urea, xylitol, Zea mays, zinc pca, andcombinations thereof.

The carrier material may comprise a modifying polymer. In someembodiments, the modifying polymer is present to maintain and/orincrease cohesiveness while reducing adhesiveness. When added with theswelling agent, the modifying polymer becomes solublized or suspended inthe swelling agent. Typically, the modifying polymer will form a viscoussolution or viscous gel when combined with the swelling agent in a ratioof modifying polymer to swelling agent of 1:9.

In some embodiments, the modifying polymer comprises a polysaccharide orderivative thereof, a (meth)acrylate or derivate thereof, or celluloseor a derivative thereof. Specific examples of modifying polymers includefor example hydroxypropyl guar; guar gum; hydroxyethyl cellulose;hydroxypropyl cellulose; hydroxypropyl methylcellulose; polymericquaternary ammonium salt of hydroxyethyl cellulose reacted with trialkylammonium substituted epoxide; copolymers of hydroxyethyl cellulose anddiallyldimethyl ammonium chloride; and derivatives and combinationsthereof.

The concentration of carrier material admixed or interdispersed with thefibrinogen hydrogel can vary depending on the selection of carriermaterial(s).

In some embodiments, such as prior to dehydration, the denaturedfibrinogen hydrogel is combined with a carrier material in an amount ofat least 0.5 wt.-% ranging up to about 10 wt.-% of the composition. Thecarrier material may comprise one or more of the previously describednatural or synthetic polymer(s). In some embodiments, the fibrinogenhydrogel comprises a (e.g. poly(N-vinyl lactam) crosslinked syntheticpolymer, as a carrier material, in an amount of at least 0.5 or 1.0wt.-% ranging up to about 4, 5, 6, 7, 8, 9, or 10 wt.-%. Higherconcentrations may be used when the synthetic polymer is uncrosslinked.In some embodiments, the fibrinogen hydrogel further comprises amodifying polymer(s) in an amount of at least 0.001, 0.005, or 0.1 wt.-%ranging up to about 1, 1.5 or 2 wt.-%. The fibrinogen hydrogel mayfurther comprise a fibrinogen hydrogel plasticizer and/or swelling agentfor the polymer of the carrier material is an amount of at least 0.5 or1 wt.-% ranging up to 5, 6, 7, 8, 9 or 10 wt.-%. The mixture offibrinogen hydrogel and carrier may be dispersed in a liquid carrier.The liquid carrier typically comprises a water/alcohol mixture.

The denatured fibrinogen hydrogel and carrier material can be combinedwith each other in any suitable manner, such as by mixing.

The mixture of denatured fibrinogen hydrogel, carrier material, andliquid carrier can be coated onto a carrier layer, such as foam, usingany suitable method including for example dip coating, forward andreverse roll coating, wire wound rod coating and die coating.

After application the liquid carrier, as well as at least a portion ofbound water of the hydrogel, is typically removed by dehydration, aspreviously described.

The dehydrated denatured fibrinogen hydrogel composition may containlittle or no water. In some embodiments, the concentration of carriermaterial can be in the same range as prior to dehydration, as previouslydescribed. For example, if the composition initially comprises 2 wt.-%of carrier material and 50 wt.-% of the water is removed, the dehydratedcomposition contain twice as much, i.e. 4 wt.-%. In other embodiments,the dehydrated fibrinogen hydrogel composition may contain 10 wt.-% to99 wt.-% of carrier material. However, as the concentration offibrinogen increases, the concentration of carrier material decreases.Thus, in some embodiments, the carrier material is no greater than 95,90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5,or 1 wt.-%.

In some embodiments, the dehydrated denatured fibrinogen hydrogelcomposition comprises a (e.g. poly(N-vinyl lactam) crosslinked syntheticpolymer, as a carrier material, in an amount of at least 15, 20, 25, or30 wt.-% and typically no greater than 90, 85, 80, 75, 70, 65, 60, 55,or 50 wt.-%. Higher concentration may be useful when the syntheticpolymer is uncrosslinked. Likewise, in some embodiments, theconcentration of modifying polymer(s) in the dehydrated fibrinogenhydrogel composition can be in the same range as previously described.In other embodiments, the dehydrated fibrinogen hydrogel may contain aconcentration ranging from 2 wt.-% to 15 wt.-% of modifying polymer(s).Likewise, in some embodiments, the concentration of fibrinogen hydrogelplasticizer and/or swelling agent for the polymer of the dehydratedfibrinogen hydrogel composition can be in the same range as previouslydescribed. In other embodiments, the dehydrated fibrinogen hydrogel mayrange from 2 wt.-% to 15 wt.-% of fibrinogen hydrogel plasticizer and/orswelling agent for the polymer of the carrier material.

In some embodiments, a carrier material may function as a pressuresensitive adhesive composition suitable for adhering to a wound.

In yet another embodiment, (e.g. dehydrated) denatured fibrinogenparticles as described herein can be admixed with various (e.g. acrylicor silicone) skin adhesives to form a fibrinogen-containing skinadhesives.

In typical embodiments, (e.g. dehydrated) denatured fibrinogen hydrogelis provided on or within a carrier layer at a coating weight that issufficient to provide the desired effect (e.g. promoting woundre-epithelialization). In some embodiments, the coating weight of the(e.g. dehydrated) fibrinogen hydrogel is typically at least 0.2, 0.5, 1,2, 3, 4, or 5 milligram per cm² and typically no greater than 30, 35,20, 25, 20, 15, 10 or 5 milligrams per cm².

The (e.g. dehydrated) fibrinogen hydrogel composition described hereinmay be utilized as a wound dressing article. The wound dressing articledescribed herein comprises a (e.g. dehydrated) fibrinogen composition ina suitable physical form such as a sheet (i.e. film), foam sheet, orfibrinogen (e.g. particles) disposed on or within a carrier layer. Thus,the (e.g. dehydrated) fibrinogen hydrogel layer can be provided invarious forms as a continuous or discontinuous layer.

In some embodiments, the (e.g. dehydrated) fibrinogen hydrogelcomposition is formed prior to combining the (e.g. dehydrated)fibrinogen hydrogel composition with a carrier material or carrierlayer. In other embodiments, a carrier layer is combined with theaqueous solution comprising fibrinogen and fibrinogen hydrogel formingsalt or the fibrinogen hydrogel prior to reducing the salt and/ordehydration. For example, a fibrous (e.g. woven or nonwoven) substratemay be placed in a rectangular pan prior to adding the fibrinogenhydrogel thereby forming a sheet of fibrin hydrogel having a fibrousscrim embedded within the hydrogel. FIGS. 1-10 as follow illustrativesome typical wound dressings articles. FIG. 1 illustrates an embodimentof a fibrinogen article, suitable for use as a wound dressing.

The fibrinogen article includes a (e.g. flexible) sheet 130 comprisingor consisting of the (e.g. dehydrated) fibrinogen gel composition.

FIG. 2 illustrates another embodiment of a fibrinogen article, suitablefor use as a wound dressing. The fibrinogen article includes a sheet offoam 230 comprising or consisting of the (e.g. dehydrated) fibrinogengel composition. The foam may having various other shapes formed forexample by molding the fibrinogen hydrogel composition (e.g. prior tohydrating) or cutting the foam into pieces after it is formed.

The fibrinogen sheet articles, such as illustrated in FIGS. 1 and 2typically have a thickness of at least 10, 15 or 20 microns andtypically no greater than 2 mm, 1 mm, 500 microns, or 250 microns. Insome embodiments, the thickness is no greater than 200, 150, 100, 75, or60 microns. The basis weight typically ranges from 2 to 10, 15, 20, 25or 30 mg/cm².

The fibrinogen concentration of the sheet article is the same as the(e.g. dehydrated) fibrinogen hydrogel as previously described.

FIG. 3 illustrates another embodiment of a fibrinogen article, suitablefor use as a wound dressing. The fibrinogen article includes a carriersheet of fibrinogen-containing foam 230 or foam lacking fibrinogen 310.The foam 230 or 310 further comprises a plurality of fibrinogenparticles 332 comprising the (e.g. dehydrated) fibrinogen hydrogeldisposed on and/or within the pores of the wound-facing surface of thefoam. The particles may be fibrinogen microbeads, fibrinogenmicrocarriers, or fibrinogen powder as previously described.

Each of the embodiments of FIGS. 1-3 may further comprise a carrierlayer disposed on a major surface of the fibrinogen-containing sheetarticle. A carrier layer is typically disposed on the opposing majorsurface as the wound-facing surface. For example, FIG. 4 illustrates anembodiment of a fibrinogen article, suitable for use as a wounddressing. The fibrinogen article includes a sheet 430 comprising orconsisting of the (e.g. dehydrated) fibrinogen gel composition (e.g.130, 230, or 310 together with 332) and a carrier layer 410.

In some embodiments, carrier layer 410 is a release liner. The releaseliner carrier may be disposed on the opposing major surface of bothmajor surfaces (not shown) such that the fibrinogen-containing sheet isbetween the release liner layers.

Various release liners are known such as those made of (e.g. kraft)papers, polyolefin films such as polyethylene and polypropylene, orpolyester. The films are preferably coated with release agents such asfluorochemicals or silicones. For example, U.S. Pat. No. 4,472,480describes low surface energy perfluorochemical liners. Examples ofcommercially available silicone coated release papers are POLYSLIK™,silicone release papers available from Rexam Release (Bedford Park,Ill.) and silicone release papers supplied by LOPAREX (Willowbrook,Ill.). Other non-limiting examples of such release liners commerciallyavailable include siliconized polyethylene terephthalate filmscommercially available from H. P. Smith Co. and fluoropolymer coatedpolyester films commercially available from 3M under the brand“ScotchPak™” release liners.

In other embodiments, the carrier layer 410 may comprise a variety ofother (e.g. flexible and/or conformable) materials such as polymericfilms and foams as well as various nonwoven and woven fibrous materials,such as gauze. In some embodiments, the carrier layer is absorbent, suchas an absorbent foam. In other embodiments, the carrier layer isnon-absorbent, such as a polymeric film.

In some embodiments, the fibrinogen article, suitable for use as a wounddressing, further comprises a (e.g. pressure sensitive) adhesive. Theadhesive may be utilized to bond the fibrinogen composition (e.g. sheetor particles) to the carrier layer. For example, FIG. 5 illustrates afibrinogen-containing sheet 530 comprising or consisting of the (e.g.dehydrated) fibrinogen gel composition and a carrier layer 510 such as apolymeric film or foam. A (e.g. pressure sensitive) adhesive layer 520bonds the fibrinogen-containing sheet 530 to the carrier layer 510.Fibrinogen-containing sheet 530 may be 130, 230, or 310 together with332 as previously described with reference to FIGS. 1-3.

In some embodiments, the fibrinogen article comprises a skin contactingadhesive for bonding the article to the skin (e.g. of a mammal such as ahuman). Such skin contact adhesive is typically a pressure sensitiveadhesive. In some embodiments, the pressure sensitive adhesive may bondfibrinogen particles to a carrier layer. The fibrinogen particles andoptionally portions of the pressure sensitive adhesive may contact thewound during use. For example, FIG. 6 illustrates another embodiment ofa fibrinogen article, suitable for use as a wound dressing. Thefibrinogen article includes a carrier layer 610 that may be a releaseliner, a polymeric film or foam, etc., a pressure sensitive adhesivelayer 620 is disposed on the carrier layer 610 and fibrinogen particles630, as described herein, are disposed on and optionally at leastpartially embedded in the pressure sensitive adhesive layer. The skincontact adhesive is typically covered by a removable release liner untiluse.

In some embodiments, the wound dressing comprises an absorbent layer.The absorbent layer is typically disposed between the wound facingfibrinogen-containing layer and a polymeric film. For example, FIG. 7illustrates another embodiment of a fibrinogen article, suitable for useas a wound dressing. The fibrinogen article includes a carrier layer 710that may be a (e.g. flexible) polymeric film. An absorbent layer 760such as a polymeric foam is disposed on the carrier layer 710. Apressure sensitive adhesive (“PSA”) layer 720 is disposed on theabsorbent layer 760 and a fibrinogen-containing layer 730 is disposed onthe pressure sensitive adhesive layer 720. The fibrinogen-containinglayer may be any of the previously described fibrinogen-containinglayers such as sheet 130, foam sheet 230, or fibrinogen particles 332.

As shown in FIG. 8, an adhesive layer 820 may be provided in adiscontinuous form, at external surfaces of absorbent layer 860, toallow penetration of wound fluids and cellular debris into the absorbentfoam layer. In some embodiments, the adhesive is a pressure sensitiveadhesive. In other embodiments, the adhesive is not a pressure sensitiveadhesive. The fibrinogen particles 832 in fibrinogen layer 830 are thusdisplayed in correspondingly discontinuous manner at the outer surfaceof absorbent layer 860. The adhesive layer 820 may extend into andthrough a portion of absorbent layer 860. Portions of the adhesive layer820 can extend over open cells 870, although it is desirable at least aportion (e.g., at least 10%, or at least 50%) of the cells at theexternal surface of absorbent layer 860 are not closed with theadhesive. Absorbent layer 860 can be adhered to (e.g. flexible) filmlayer 810 by a suitable adhesive layer. In this embodiment, thefibrinogen particles may be fibrinogen microbeads, fibrinogenmicrocarriers, or fibrinogen powder as previously described. In oneembodiment, a solution of pressure-sensitive adhesive can be sprayedonto a carrier layer such as an open cell foam at a suitable coatingweight (e.g., 5-15 mg/cm²) and after drying the PSA layer, fibrinogenparticles can be coated onto the adhesive coated surface. The fibrinogenparticles can thus be deposited on an exterior surface of the foam withsome additional loading into pores of the open cell foam. Such afibrinogen particles/PSA/absorbent foam construct has been observed toreadily absorb moisture. This approach is also suitable forincorporating fibrinogen particles on elastomeric carrier layers.

In another embodiment, a fibrinogen particle layer can be disposed on apressure-sensitive adhesive layer, which in turn is disposed on aflexible, porous, non-woven backing layer. The non-woven backing layercan be reinforced with filaments (e.g., polyester filaments) for addedstrength. An example of such a non-woven-backing coated with a(hypoallergenic) pressure-sensitive adhesive can include sterile skinclosure strips (e.g., STERI-STRIPS, available from 3M Co., St. Paul,Minn.). The addition of a fibrinogen (e.g. particle) layer to suchsterile skin closure strips can have beneficial effects, for example, inscar management at incision or wound sites (i.e., to reduce scarformation).

In other embodiments, a skin contact adhesive is located at theperiphery of the article such that the adhesive typically contacts theskin outside of the wound such as near the periphery of a wound. Theskin contact adhesive is typically covered by a removable release lineruntil use. For example, FIG. 9 illustrates another embodiment of afibrinogen article, suitable for use as a wound dressing. The fibrinogenarticle includes a carrier layer 960 that is typically a polymeric film,a pressure sensitive skin adhesive 920 is disposed at peripheral regionsof the film, a fibrinogen sheet 930 is disposed on film 960 in themiddle region between adhesive 920, a removable release liner 910 isdisposed on the fibrinogen sheet and the adhesive. Alternatively, therelease liner may be disposed only upon the adhesive as depicted in FIG.10. In FIG. 11, the (e.g same) skin contact adhesive is utilized to bondthe fibrinogen sheet to the polymeric film carrier layer 960.

In some embodiments, the carrier layer of the wound dressing is aflexible film layer, (also referred to as a “backing” layer), typicallyincludes a liquid impervious, moisture vapor permeable (e.g.breatheable) polymeric film. The liquid impervious, moisture vaporpermeable polymeric film is a conformable organic polymeric materialthat preferably retains its structural integrity in a moist environment.Herein, “conformable” films are those that conform to a surface, evenupon movement of the surface, as with the surface of a body part. Assuch, when the flexible film layer is applied to an anatomical feature,it conforms to the surface even when the surface is moved. The preferredflexible film layer is also conformable to animal anatomical joints.When the joint is flexed and returned to its unflexed position, theflexible film layer stretches enough to accommodate the flexion of thejoint, but is resilient enough to continue to conform to the joint whenthe joint is returned to its unflexed condition. A description of thischaracteristic of flexible film layers preferred for use in wounddressings of the present disclosure can be found, for example, in U.S.Pat. No. 5,088,483 (Heineke) and 5,160,315 (Heineke).

Suitable films have a composition and thickness that allow for thepassage of moisture vapor through them. The film aids in the regulationof water vapor loss from the wound area beneath the dressing. The filmalso acts as a barrier to both bacteria and to liquid water or otherliquids.

The moisture vapor permeable polymeric films for use as flexible filmlayers in the present disclosure can be of a wide range of thicknesses.In some embodiments, the flexible film layers have a thickness of atleast 10 or 12 microns ranging up to 250 microns. In some embodiments,the flexible film layer has a thickness no greater than 75 microns.

Moisture vapor transmission rate (“MVTR”) properties of a wound dressingarticle are important to allow the wound under the wound dressing toheal in moist conditions without causing the skin surrounding the woundto become macerated, and to facilitate optimum wear time and ease ofremoval.

A dry MVTR (or upright MVTR) of wound dressings or various componentsthereof, including the flexible film layer, can be measured by ASTME-96-80 (American Society of Testing Materials) at 40° C. and 20%relative humidity using an upright cup method. Wet MVTR (or invertedMVTR) can be measured by the same method except that the sample jars areinverted so the water is in direct contact with the test sample.

In some embodiments, the film has a dry MVTR that is less than the wetMVTR of the film. For example, the film may have a dry MVTR of at least300 g/m²/24 hours and a wet MVTR of at least 500, 1000, 2000 or 3000g/m²/24 hours. In some embodiments, the film has a wet MVTR greater10,000 g/m²/24 hours or 15,000 g/m²/24 hours.

Examples of suitable materials for the liquid-impervious, moisture-vaporpermeable polymeric films of the flexible film layer include syntheticorganic polymers including, but not limited to: polyurethanescommercially available from B.F. Goodrich, Cleveland, Ohio, under thetrade designation ESTANE, including ESTANE 58237 and ESTANE 58245;polyetheramide block copolymers commercially available from Elf Atochem,Philadelphia, Pa., under the trade designation PEBAX, including PEBAX MV1074; polyether-ester block copolymers commercially available fromDuPont, Wilmington, Del., under the trade designation HYTREL; andthermoplastic elastomers commercially available from DSM EngineeringPlastics, Evansville, Ind., under the trade designation ARNITEL VT. Thepolymeric films can be made of one or more types of monomers (e.g.,copolymers) or mixtures (e.g., blends) of polymers. Preferred materialsare thermoplastic polymers, e.g., polymers that soften when exposed toheat and return to their original condition when cooled. A particularlypreferred material is a thermoplastic polyurethane.

Flexible films of the wound dressing articles of the present disclosurecan also include other breathable materials including, for example,nonwoven, woven, and knit webs, porous films (e.g., provided byperforations or microporous structure), foams, paper, or other knownflexible films. A preferred flexible film includes a combination of aliquid-impervious, moisture-vapor permeable polymeric film and amoisture-vapor permeable nonwoven web that can, among other advantages,impart enhanced structural integrity and improved aesthetics to thedressings. These layers of film and web may or may not be coextensive. Apreferred such nonwoven web is a melt processed polyurethane (such asthat available under the trade designation MORTHANE PS-440 from MortonInternational, Seabrook, N.H.), or hydroentangled nonwoven polyester orrayon-polyester webs (such as those available under the tradedesignation SONTARA 8010 or SONTARA 8411 from DuPont, Wilmington, Del.).

In some embodiments, flexible film layer is translucent,semi-transparent, or transparent, although this is not a requirement.Some examples of wound dressings that include a transparent ortranslucent flexible film layer are available under the tradedesignation TEGADERM, available from 3M Co., St. Paul, Minn.

A low adhesion coating (low adhesion backsize or LAB) can be provided onthe flexible film layer on the side that may come into contact with anoptional support layer. The low adhesion coating reduces the need tochange the dressing due to unwanted dressing removal when other tapes ordevices are placed on the dressing and removed, and reduces the surfacefriction of the dressing on linen or other fabrics, thereby offeringadditional protection against the accidental removal of dressing. Adescription of a low adhesion coating material suitable for use with awound dressing article of the present disclosure can be found in U.S.Pat. No. 5,531,855 (Heineke) and 6,264,976 (Heineke).

In some embodiments, the wound dressing comprises an absorbent layer. Insome embodiments, the absorbent layer can include an absorbent foamlayer, or at least a portion of an absorbent foam layer disposed on theflexible film layer. A suitable foam layer can include, for example, anopen cell foam selected from among the open cell foams described in U.S.Pat. No. 6,548,727 (Swenson). Suitable open cell foams preferably havean average cell size (typically, the longest dimension of a cell, suchas the diameter) of at least about 30 microns, more preferably at leastabout 50 microns, and preferably no greater than about 800 microns, morepreferably no greater than about 500 microns, as measured by scanningelectron microscopy (SEM) or light microscopy. Such open cell foams whenused in wound dressings of the present disclosure allow transport offluid and cellular debris into and within the foam. In some embodiments,the foam includes a synthetic polymer that is adapted to form aconformable open cell foam that absorbs wound exudate. Examples ofsuitable materials for the absorbent, substantially nonswellable foamsinclude synthetic organic polymers including, but not limited to:polyurethanes, carboxylated butadiene-styrene rubbers, polyesters, andpolyacrylates. The polymeric foams can be made of one or more types ofmonomers (e.g., copolymers) or mixtures (e.g., blends) of polymers.Preferred foam materials are polyurethanes. A particularly preferredfoam is a polyurethane, available under the trade designation POLYCRIL400 from Fulflex, Inc., Middleton, R.I. In other embodiments, the foamcomprises or consists of the (e.g. dehydrated) fibrinogen hydrogel.

In another embodiment, the absorbent layer may comprise a non-woven or afiber material. In an embodiment where the absorbent material includes afiber material, the fiber material can be a sheath-core fiber having acentral core of absorbent fiber and a sheath comprisingpressure-sensitive adhesive.

In some embodiments, the absorbent layer may extend around a peripheralregion of the wound dressing, to absorb fluids that might otherwiseaccumulate on skin and result in undesirable skin degradation (e.g.,maceration). In such embodiments, an absorbent layer would not need tobe included in a more central region of the wound dressing (e.g., theportion of the wound dressing that is in contact with the wound, orpositioned over the wound).

The fibrinogen article, suitable for use as a wound dressing, maycomprise various adhesives to bond layers of the article. The fibrinogenarticle may also comprises various PSAs for bonding the article to skin.The (e.g. PSA) adhesive layer can be continuous, discontinuous, patterncoated, or melt-blown, for example.

PSAs typically have a storage modulus (G′) of less than 1×10⁶ dynes/cm²at 25° C. and a frequency of 1 hertz. In some embodiments, the PSA hasstorage modulus (G′) of less than 9, 8, 7, 6, 5, 4, or 3×10⁵ dynes/cm²at 25° C. and a frequency of 1 hertz.

Examples of PSAs include rubber based adhesives (e.g., tackified naturalrubbers, synthetic rubbers, and styrene block copolymers), acrylics(e.g., polymerized (meth)acrylates), poly(alpha-olefins), polyurethanes,and silicones. Amine containing polymers can also be used which haveamine groups in the backbone, pendant thereof, or combinations thereof.A suitable example includes a poly(ethyleneimine).

Useful adhesives can be any of those that are compatible with skin anduseful for wound dressings, such as those disclosed in U.S. Pat. Nos.Re. 24,906 (Ulrich), 5,849,325 (Heinecke et al.), and 4,871,812 (Lucastet. al.) (water-based and solvent-based adhesives); U.S. Pat. No.4,833,179 (Young et al.) (hot-melt adhesives); U.S. Pat. No. 5,908,693(Delgado et al.) (microsphere adhesives); U.S. Pat. Nos. 6,171,985 and6,083,856 (both to Joseph et al.) (low trauma fibrous adhesives); and,U.S. Pat. No. 6,198,016 (Lucast et al.), 6,518,343 (Lucast et al.), and6,441,082 (Gieselman) (wet-skin adhesives). Inclusion of medicaments orantimicrobial agents in the adhesive is also contemplated, as describedin U.S. Pat. No. 4,310,509 (Berglund) and 4,323,557 (Rosso).

The adhesive can be coated on the carrier layer by a variety ofprocesses, including, direct coating, lamination, and hot lamination. Insome embodiments, the adhesive may be coated as a microstructuredadhesive layer.

Silicone and acrylic based pressure sensitive adhesives are mostcommonly utilized for adhering to the skin, whereas the other classes ofadhesives can be utilized to bond layers of the fibrinogen articlesuitable for use as a wound dressing.

Silicone PSAs include two major components, a polymer or gum, and atackifying resin. The polymer is typically a high molecular weightpolydimethylsiloxane or polydimethyldiphenyl-siloxane, that containsresidual silanol functionality (SiOH) on the ends of the polymer chain,or a block copolymer including polydiorganosiloxane soft segments andurea terminated hard segments. The tackifying resin is generally athree-dimensional silicate structure that is endcapped withtrimethylsiloxy groups (OSiMe₃) and also contains some residual silanolfunctionality. Examples of tackifying resins include SR 545, fromGeneral Electric Co., Silicone Resins Division, Waterford, N.Y., andMQD-32-2 from Shin-Etsu Silicones of America, Inc., Torrance, Calif.Manufacture of typical silicone PSAs is described in U.S. Pat. No.2,736,721 (Dexter). Manufacture of silicone urea block copolymer PSA isdescribed in U.S. Pat. No. 5,214,119 (Leir et al.).

In some embodiments, the silicone adhesive may be characterized asgentle to skin such as described in US2011/0212325, US2011/0206924,US2011/0206923, US2013/0040073, U.S. Pat. No. 7,407,709 and U.S. Pat.No. 787,268.

In some embodiments, the PSAs is an acrylic PSAs typically having aglass transition temperature of about −20° C. or less and may includefrom 100 to 60 weight percent of a C4-C12 alkyl ester component such as,for example, various (meth)acrylate monomers including isooctylacrylate, 2-ethyl-hexyl acrylate and n-butyl acrylate and from 0 to 40weight percent of a polar component such as, for example, acrylic acid,methacrylic acid, ethylene, vinyl acetate, N-vinyl pyrrolidone andstyrene macromer.

Suitable acidic monomers for preparing (meth)acrylic PSAs include thosecontaining carboxylic acid functionality such as acrylic acid,methacrylic acid, itaconic acid, and the like; those containing sulfonicacid functionality such as 2-sulfoethyl methacrylate; and thosecontaining phosphonic acid functionality. Preferred acidic monomersinclude acrylic acid and methacrylic acid.

Additional useful acidic monomers include, but are not limited to, thoseselected from ethylenically unsaturated carboxylic acids, ethylenicallyunsaturated sulfonic acids, ethylenically unsaturated phosphonic acids,and mixtures thereof. Examples of such compounds include those selectedfrom acrylic acid, methacrylic acid, itaconic acid, fumaric acid,crotonic acid, citraconic acid, maleic acid, oleic acid, B-carboxyethylacrylate, 2-sulfoethyl methacrylate, styrene sulfonic acid,2-acrylamido-2-methylpropane sulfonic acid, vinyl phosphonic acid, andthe like, and mixtures thereof.

Due to their availability, acidic monomers of the present invention aretypically the ethylenically unsaturated carboxylic acids. When evenstronger acids are desired, acidic monomers include the ethylenicallyunsaturated sulfonic acids and ethylenically unsaturated phosphonicacids. Sulfonic and phosphonic acids generally provide a strongerinteraction with a basic polymer. This stronger interaction can lead togreater improvements in cohesive strength, as well as higher temperatureresistance and solvent resistance of the adhesive.

Suitable basic monomers for preparing (meth)acrylic PSAs include thosecontaining amine functionality such as vinyl pyridine,N,N-diethylaminoethyl methacrylate, N,N-dimethylamino-ethylmethacrylate, N,N-diethylaminoethyl acrylate, N,N-dimethylaminoethylacrylate, and N-t-butylaminoethyl methacrylate. Preferred basic monomersinclude N,N-dimethylaminoethyl methacrylate, and N,N-dimethylaminoethylacrylate.

The (meth)acrylic PSAs may be self-tacky or tackified. Useful tackifiersfor (meth)acrylics are rosin esters such as that available under thetrade name FORAL 85 from Hercules, Inc., aromatic resins such as thatavailable under the trade name PICCOTEX LC-55WK from Hercules, Inc.,aliphatic resins such as that available under the trade name PICCOTAC 95from Hercules, Inc., and terpene resins such as that available under thetrade names PICCOLYTE A-115 and ZONAREZ B-100 from Arizona Chemical Co.Other materials can be added for special purposes, includinghydrogenated butyl rubber, pigments, and curing agents to vulcanize theadhesive partially. Examples of acid-modified tackifiers includeacid-modified polyhydric alcohol rosin ester tackifiers as described inU.S. Pat. No. 5,120,781 (Johnson).

In certain embodiments, the (e.g. acrylic) PSA comprises polymerizedunit of a poly(alkylene oxide) such as poly(ethylene oxide) and/orpoly(propylene oxide). The PSA typically comprises at least 5, 10 or 15wt.-% and typically no greater than about 30 wt.-% of polymerizedpoly(alkylene oxide).

In some embodiments, a poly(alkylene oxide) copolymer is blended with a(meth)acrylic copolymer. Examples of useful poly(alkylene oxide)copolymers include, but are not limited to, those poly(alkylene oxide)copolymers available under the trade designations TETRONIC(tetrafunctional block copolymers derived from sequential addition ofpropylene oxide and ethylene oxide to ethylene diamine with hydrophilicendblocks) and TETRONIC R (tetrafunctional block copolymers derived fromsequential addition of propylene oxide and ethylene oxide to ethylenediamine with hydrophobic endblocks) copolymers available from BASF, Mt.Olive, N.J.; PLURONIC (triblock copolymers with poly(ethylene oxide) endblocks and poly(propylene oxide) midblock) and PLURONIC R (triblockcopolymers with poly(propylene oxide) endblocks and poly(ethylene oxide)midblock) copolymers available from BASF; UCON Fluids (random copolymersof ethylene oxide and propylene oxide) available from Union Carbide,Danbury, Conn. Various combinations of poly(alkylene oxide) copolymerscan also be used. Preferred nonreactive hydrophilic polymer componentsare block copolymers of polyethylene glycol and propylene glycolavailable from BASF, Germany under the trade name PLURONIC.

In other embodiments, a poly(alkylene oxide) monomer having acopolymerizable (e.g. vinyl) group is included during the polymerizationof the acrylic polymer. Commercially available monomers include2-(2-ethoxyethoxy)ethyl acrylate which is available under the tradedesignation “SR-256” from Sartomer Company, West Chester, Pa.; themethoxy poly(ethylene oxide) acrylate which is available under the tradedesignation “No. 8816” from Monomer-Polymer & Dajac Laboratories, Inc.,Trevose, Pa.; the methoxy poly(ethylene oxide) methacrylates of 200Daltons, 400 Daltons, and 1000 Daltons which are available under thetrade designations “No. 16664”, “No. 16665” and “No. 16666”,respectively, from Polysciences, Inc., Warrington, Pa.; and the hydroxypoly(ethylene oxide) methacrylate which is available under the tradedesignation “No. 16712” from Polysciences, Inc., Warrington, Pa.

Examples of acrylic adhesive compositions include a 97:3 iso-octylacrylate:acrylamide copolymer 65:15:20 2-ethylhexylacrylate:acrylicacid:copolymer blended with a nonreactive polyakylene oxide copolymerunder the trade designation PLURONIC. Other suitable examples include a90:10 iso-octyl acrylate:acrylic acid copolymer, a 70:15:15 isooctylacrylate:ethylene oxide acrylate:acrylic acid terpolymer, and a 25:69:62-ethylhexylacrylate:butyl acrylate:acrylic acid terpolymer. Additionaluseful adhesives are described in U.S. Pat. Nos. 3,389,827, 4,112,213,4,310,509, and 4,323,557.

Inclusion of medicaments or antimicrobial agents in the adhesive is alsocontemplated, as described in U.S. Pat. Nos. 4,310,509 and 4,323,557.

Pressure sensitive adhesives for wound dressings preferably transmitmoisture vapor at a rate greater to or equal to that of human skin.While such a characteristic can be achieved through the selection of anappropriate adhesive, it is also contemplated in the present disclosurethat other methods of achieving a high relative rate of moisture vaportransmission may be used, such as pattern coating the adhesive on thebacking, as described in U.S. Pat. No. 4,595,001 (Potter et al.).

A composite of flexible film layer coated with pressure-sensitiveadhesive layer preferably has a moisture vapor transmission rate of atleast 300 g/m²/24 hrs/37° C./100%-10% relative humidity (“RH”), morepreferably at least 700 g/m²/24 hrs/37° C./100%-10% RH, and even morepreferably at least 2000 g/m²/24 hrs/37° C./100%-10% RH using theinverted cup method as described in U.S. Pat. No. 4,595,001.

In some embodiment, the method of making a fibrinogen article generallycomprises providing a (e.g. dehydrated) fibrinogen composition anddisposing the fibrinogen composition on or within a carrier. In someembodiments, the carrier is a carrier layer such as a release liner, apolymeric film or foam, or a nonwoven or woven fibrous material. Whenthe fibrinogen composition is in a particle form, the methods of makingthe wound dressing can include distributing fibrinogen particles onto a(e.g. pressure-sensitive) adhesive layer disposed on a carrier.Alternatively, the fibrinogen particles can be suspended in a liquid(e.g., an inert, volatile fluorinated liquid) and spray dried in adehydrated form onto the surface of a (e.g. pressure-sensitive adhesive)layer disposed on a carrier layer. Examples of suitable wound dressingsthat include a pressure-sensitive adhesive layer disposed on flexiblefilm layer include TEGADERM wound dressings (e.g., TEGADERM 1626)available from 3M Co., St. Paul, Minn. In one embodiment, thefibrinogen-containing layer (e.g. sheet or particles) are applied to thesurface of a pressure-sensitive adhesive layer of a TEGADERM wounddressing.

A wound dressing article of the present description is typicallyprovided in a package format (i.e., positioned in a sealed package). Theinterior of the sealed package is typically sterile. Examples of wounddressing packages suitable for use with the wound dressings and methodsof this disclosure include, for example, polymeric packages and foilpackages. A wide variety of polymeric materials may be used to makenon-porous packages suitable for use with the wound dressings. Thepackaging material may be, for example, polyethylene, polypropylene,copolymers of ethylene and propylene, polybutadiene, ethylene-vinylacetate, ethylene-acrylic acid, or ionomeric films. Suitable foilpackages can include aluminum foil packages. In some embodiments, thepackaging material may be used as sheets of material which are placedabove and below the wound dressing and then sealed on four sides togenerate the package. In other embodiments, a pre-made pouch is utilizedwhich has 3 sides already sealed. After the wound dressing article isplaced within the pouch the fourth side is sealed to form the package.Sealing of the package can be achieved by heat sealing (i.e. by theapplication of heat and pressure to form a seal) or the use of adhesivesealants can be used to seal the packages (for example pressuresensitive adhesive sealants or cold seal sealants). Typically, heatsealing is used. Additionally, packaging systems can be used whichinclude placing the wound dressing in a porous package that is thenplaced in a non-porous package, such as a foil package. The foil packageprevents moisture loss prior to use and the porous package permits easyhandling during use.

An advantage of a wound dressing article of the present disclosure isthat it can be sterilized by a terminal sterilization process thatincludes exposure to ethylene oxide or, advantageously,gamma-irradiation. This irradiation can be carried out whether or notthe wound dressing article is contained within a package. The exposuretimes and levels of radiation doses applied to the wound dressings toachieve sterilization can vary based upon a variety of factors,including the gamma equipment used as well as the inherent bioburdenlevels present in the wound dressing. Typically, to achievesterilization of a wound dressing, a Sterility Assurance Level (SAL) of10⁻⁶ is required. This SAL level is typically achieved by exposing thewound dressing to a minimum cumulative gamma irradiation dose. Dependingon the bioburden levels in an unsterilized dressing and the size of thedressing, the minimum cumulative dose can range from about 10 kGy toabout 35 kGy. Typically the minimum cumulative dose is about 15 to 30kGy. In other embodiment, a dosage of about 50 to 60 kGy may beutilized. The required gamma radiation dose to achieve sterility can bedone in a single pass or multiple passes through the gamma irradiationsterilizer. For example, exposing the wound dressing to 5 sterilizationcycles using a dose of 5 kGy per cycle would be similar to exposing thewound dressing to one dose of 25 kGy of gamma irradiation. Due to laborand time constraints, it is generally desirable to minimize the numberof passes that a wound dressing experiences through the gammairradiation sterilizer. Typically, it is desirable that the number ofpasses through the sterilizer be five or less, and it may be even moredesirable for the number of passes to be two or less. Exposure time maybe viewed as the time a sample to be sterilized is exposed to the gammaradiation. Typically the exposure time is on the order of hours.

Gamma radiation is a suitable method to sterilize the wound dressings ofthis disclosure. Exposure of the wound dressings of this disclosure to asuitable level gamma irradiation does not produce a comparable loss ofre-epithelialization performance.

The ability to use terminal sterilization can provide an advantage overother forms of wound dressings that include, for example, a liquid.Without being bound by theory, aqueous solutions or suspensions ofproteins such as fibrinogen and thrombin can be expected to undergointer-chain crosslinking during terminal sterilization that involvesgamma-irradiation. In a dry format, a protein will often undergo chainscission (i.e., degradation) and thereby lose enzymatic activity. Thus,gamma-irradiation of the reagents for a polymerization (e.g., fibrinogenand/or thrombin) may result in crosslinking and/or chain scission of theseparate reagents, and thus no reaction (or no polymerization) to formfibrin. Depending on the level of gamma-irradiation, fibrin may alsoundergo some chain scission, although even with low levels ofdegradation, the gamma-irradiated fibrin still can be recognized bycells to obtain the desired re-epithelialization effect.

The (e.g. dehydrated) fibrinogen hydrogel in its various physical formscan be utilized for the treatment of wounds. Thus, in anotherembodiment, a method of treatment of a (e.g. mammal or human) wound isdescribed providing the fibrinogen composition as described herein or awound dressing comprising the described fibrinogen composition andproviding the fibrinogen composition proximate a wound. In typicalembodiments, the fibrinogen-containing layer (e.g. sheet, foam,particles) is in direct contact with at least a portion or portions ofthe wound. Alternatively, it is surmised that the fibrinogen-containinglayer may be in close proximity, yet not in direct contact. For example,it is contemplated that an absorbent porous carrier layer, such as agauze, may comprise the fibrinogen-containing layer on the opposingsurface as the wound facing surface. During use fluids of the woundpenetrate through the absorbent porous carrier layer thereby degradingthe fibrinogen-containing layer.

The fibrinogen composition has been shown to increase the rate ofre-epithelialization in both in-vivo porcine studies and in-vitrostudies using human primary isolated cells. In some embodiments, there-epithelialization was 2 times faster than the control (same dressingwithout (e.g. dehydrated) fibrinogen hydrogel).

The dehydrated fibrinogen composition was also been found to affect theformation of prohealing and anti-healing biomarkers such as growthfactors, proteases, cytokines as commonly known in the art. (See Murphy,K. (2012). Janeway's Immunobiology (E. Lawrence Ed. 8th ed.): Garlandscience). In some embodiments, the formation of VEGF—vascularendothelial growth factor was at least 1, 2, 3, or 4 times greater thanthe control. In some embodiments, the EGF—epidermal growth factor was asleast 1 or 2 times greater than the control. In some embodiments, theformation of matrix metalloproteinase—MMP1 and/or MMP8—was at least 1,2, 3, 4, 5, 6, 7, 8, or 9 times greater than the control. In someembodiments, the formation of matrix metalloproteinase—MMP9—was at least10, 20, 30, 40, 50, 60, 70, or 80 times greater than the control. Insome embodiments, the formation of TIMP1-tissue inhibitor ofmetalloproteinase was at least 1, 2, 3, or 4 times greater than thecontrol. Prohealing markers IL-4, IL-6, IL-10, EGF, FGF-basic were thesame as the control, indicating no effect. Further, anti-healingbiomarkers TNF-alpha, ILI-alpha, IL-1beta, IL-2 were all below thedetection limit of the assay, indicating a low pro-inflammatory profile.

All patents and patent applications cites herein are incorporated byreference. Other modifications and variations to the present disclosuremay be practiced by those of ordinary skill in the art, withoutdeparting from the spirit and scope of the present disclosure. It isunderstood that aspects of the various embodiments may be interchangedin whole or part or combined with other aspects of the variousembodiments. The preceding description, given in order to enable one ofordinary skill in the art to practice the claimed disclosure, is not tobe construed as limiting the scope of the disclosure, which is definedby the claims and all equivalents thereto.

EXAMPLES

Unless otherwise noted, all parts, percentages, ratios, etc. in theExamples and the rest of the specification are by weight. “Weightpercent” is in some places abbreviated as “wt.-%”.

Materials

CaCl₂, NaCl were obtained from SIGMA-Aldrich (Milwaukee, Wis.). Othermaterials are listed as used in the Examples below.

Preparatory Example P1. Preparation of Fibrinogen Solution

Preparatory Example P1-A, a fibrinogen solution in water, was preparedby dissolving 5.1 grams fibrinogen powder (Bovogen Biologicals,Australia) in 24.9 grams of deionized water (Honeywell InternationalInc, USA) at 40° C. The fibrinogen solutions were also prepared atdifferent concentrations. Fibrinogen concentration is important forobtaining a smooth de-natured sheet. For a coat-able solution, a minimumviscosity of 200 cps is preferred. The fibrinogen concentrations, alongwith subsequent viscosities, of examples P1-A through P1-H are listedbelow in TABLE 1. It was not possible to dissolve fibrinogen atconcentrations at or above 18% w/w due to the high viscosity thatimmobilized the system.

TABLE 1 FIBRINOGEN/WATER SOLUTIONS AT VARIOUS CONCENTRATIONS EXAMPLEP1-A P1-B P1-C P1-D P1-E P1-F P1-G P1-H Fibrinogen (g) 5.1 12 12.8 13.213.6 14 14.4 15.2 Deionized water (g) 24.9 68 67.2 66.8 66.4 66 65.664.8 Concentration w/w (%) 17 15 16 16.5 17 17.5 18 19 Viscosity (cps)115 230 725 230 387 gel gel

Comparative Example 1. Thermally Denatured Fibrinogen Films

Comparative Example C1-A was prepared by taking Preparatory Example P1-Aand adding 3.84 grams of glycerol anhydrous (J.T. Baker, USA) was addedand mixed until obtaining a homogeneous solution. The solution wasstored without agitation for 12 hours to allow the bubbles/foam (createdby agitation) to settle. The solution was cast at a thickness of 100micrometers onto a silicone release liner. The coated fibrinogensolution was heated at 80° C. to allow denaturation until a cleardenatured fibrinogen film was obtained. A low pressure nitrogen streamwas applied to the film to aid in evaporation of water.

Additional comparative examples of thermally denatured fibrinogen films,Comparative Examples C1-B and C1-C were also prepared at differentglycerol concentrations (w/w to dry fibrinogen). Dissolution of thefibrinogen was completed as in example P1-A. The glycerol addition anddenaturation proceeded as in example C1-A.

TABLE 2 COMPARATIVE EXAMPLES C1-A, C1-B, C1-C EXAMPLE C1-A C1-B C1-CFibrinogen (g) 5.1 13.6 13.6 Deionized water (g) 24.9 64.9 56.1 Glycerol(g) 3.84 1.5 10.26 Glycerol concentration to dry fibrinogen w/w (%) 4310 43

Preparatory Example P2. Preparation of Fibrinogen Solutions with CalciumChloride

The Fibrinogen powder (Bovogen Biologicals, Australia) was analyzed byion chromatography for citrate content and was determined to containapproximately 14 w/w % citrate. It is also estimated to contain anadditional 12% sodium chloride. Sodium citrate, an anti-coagulant salt,comes with the fibrinogen powder. However, it is known fromUS2016/024141 that excessive salt content has a negative effect on woundhealing. Preparatory Example 2 was prepared as thermally denaturedfibrinogen films with the inclusion of calcium chloride. Calciumchloride was added to exchange sodium citrate to calcium citrate. Thecalcium chloride concentrations of Preparatory Examples P2-A and P2-Bare listed below in TABLE 3. Dissolution of the fibrinogen proceeded asin example P1-A, except that calcium chloride was added after thefibrinogen and before the water. Glycerol addition and denaturationproceeded as in Comparative Example C1-A. The ingredients forPreparatory Examples P2-A and P2-B are listed below in TABLE 3.

TABLE 3 PREPARATORY EXAMPLES P2-A AND P2-B WITH VARIOUS CALCIUM CHLORIDECONCENTRATIONS EXAMPLE P2-A P2-B Fibrinogen (g) 5.1 5.1 Deionized water(g) 24.9 24.9 Calcium chloride (g) 0.25 0.025 Glycerol (g) 3.84 3.84Calcium chloride concentration w/w (%) 0.74 0.074

Example 1: Washed, De-Salted Fibrinogen Films

The dehydrated denatured fibrinogen film of Comparative Example C1-A wasconverted to working Example 1 by the following washing procedure toreduce the salt content in the denatured fibrinogen films. A sample ofComparative Example C1-A was soaked in 200 grams of fresh distilledwater/glycerol (85/15) mixture solution for 5 minutes to form workingExample 1A. A sample of Comparative Example C1-A was soaked in 200 gramsof fresh distilled water/glycerol (85/15) mixture solution for 40minutes to form working Example 1B. After the soaking step the filmsamples were dried at 80° C. for 30 minutes. This low salt thermaldehydrated denatured fibrinogen film of Example 1A and Example 1B waseasily removed from the release liner as a flexible and transparentfilm.

The conductivity testing was performed by first cutting 5.1 cm×5.1 cmdry samples and placing them in glass jars with a lid and sterile waterfor irrigation (Baxter, Lot G122242, expiration date of March 2019) Theamount of water added was such that the fibrinogen sample weight wasapproximately 1% by weight of the total solution. The samples wereallowed to sit in the water for a minimum of 10 minutes and then theconductivity of the solution was measured.

The conductivity testing was performed using a VWR Symphony B30PCIBenctop Multi Parameter Meter-pH, Conductivity, ISE. Conductivityresults for Example 1A and Example 1B and Comparative Example C1-A areshown in TABLE 4. The salt content of Comparative Example C1-A isestimated to be approximately 15 wt. % in the dried fibrinogen film withglycerol. The salt content of washed de-salted and dried Examples 1A and1B is estimated to be approximately 2.7 wt. % and 1.6 222 wt. %,respectively.

TABLE 4 CONDUCTIVITY TEST RESULTS FOR WORKING EXAMPLE 1 EXAMPLE 1A 1BC1-A Conductivity (mS/cm) 0.55 0.33 3.07

Example 2. In-Vivo Evaluation of Fibrinogen Films with Low Salt Content

Low salt, washed Examples 2A and 2B may be analyzed for percentre-epithelialization according to the in-vivo re-epithelializationprocedure described in 75852. Examples 2A and 2B would not irritate thewound or cause inflammation and would be expected to demonstrate anincreased rate of re-epithelialization as well an increases of at leastone wound healing biological marker.

What is claimed is:
 1. A fibrinogen composition comprising denaturedfibrinogen hydrogel having a fibrinogen concentration ranging from 0.1to 15 wt.-%; fibrinogen hydrogel forming salt at a concentration lessthan a threshold concentration to form the fibrinogen hydrogel.
 2. Thefibrinogen composition of claim 1, wherein the fibrinogen compositioncomprises at least 50 wt.-% water.
 3. The fibrinogen composition ofclaim 1, wherein the fibrinogen hydrogel forming salt concentration isless than 0.45 wt-% of the fibrinogen composition.
 4. The fibrinogencomposition of claim 1, wherein the fibrinogen hydrogel forming saltcomprises sodium citrate optionally in combination with sodium chloride.5. The fibrinogen composition of claim 1, further comprising aplasticizer.
 6. The fibrinogen composition of claim 5 wherein theplasticizer comprises a sugar alcohol, an alkane diol, or a combinationthereof.
 7. The fibrinogen composition of claim 1, further comprising acarrier material in an amount ranging from 0.1 to about 50 wt.-%.
 8. Thefibrinogen composition of claim 7 wherein the carrier material comprisesa water-soluble polymer.
 9. The fibrinogen composition of claim 8,wherein the water-soluble polymer comprises polymerized units of N-vinyllactam polymer.
 10. The fibrinogen composition of claim 7, wherein thecarrier material further comprises a swelling agent.
 11. The fibrinogencomposition of claim 1, wherein the fibrinogen composition is at leastpartially dehydrated.
 12. A fibrinogen composition comprising dehydrateddenatured fibrinogen hydrogel; wherein the fibrinogen compositioncomprises salt at a concentration no greater than 20 wt.-%.
 13. Thefibrinogen composition of claim 12, wherein the fibrinogen compositioncomprises at least 5 wt.-% fibrinogen.
 14. The fibrinogen composition ofclaim 12, wherein the fibrinogen composition comprises less than 50wt.-% water.
 15. The fibrinogen composition of claim 12, wherein thesalt concentration is less than 15, 10, or 5 wt.-% of the fibrinogencomposition.
 16. The fibrinogen composition of claim 12, furthercomprising a plasticizer.
 17. The fibrinogen composition of claim 12,further comprising a carrier material.
 18. The fibrinogen composition ofclaim 17, wherein the fibrinogen composition is interdispersed with 0.5to 99 wt.-% of the carrier material.
 19. The fibrinogen composition ofclaim 17, wherein the fibrinogen composition is disposed on the carriermaterial.
 20. The fibrinogen composition of claim 17, wherein thecarrier material comprises a water-soluble polymer.